The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study.
 
Michael Wang
Honoraria - AstraZeneca; BeOne; Binacea; Bristol Myers Squibb; CAHON; East Virginia Medical School; Editorial Medica AWWE SA; Instituto Scientifico Romagnolo; Janssen; Kite, a Gilead company; Mayo Clinic; Medscape/WebMD; Merck; MJH Life Sciences; MSC National Research Institute of Oncology; Pfizer; Physicans' Education Resource; Plexus; PromCon S.R.E; Research to Practice; Studio ER Congressi; VJHemonc
Consulting or Advisory Role - AstraZeneca; Boxer Capital; Bristol Myers Squibb; Galapagos NV; Genmab; Innocare; Janssen; Kite, a Gilead company; Lilly; Merck; Oncternal Therapeutics; Pepromene; PER; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bantam Pharmaceutical (Inst); BeOne (Inst); Genentech (Inst); Genmab (Inst); Innocare (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Kite, a Gilead company; Physicans' Education Resource
 
Marc Hoffmann
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Genentech; Kite/Gilead; Novartis; Pharmacyclics/Janssen
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene
Other Relationship - Novartis
 
Tomasz Wrobel
Honoraria - Amgen; BeiGene; Gilead Sciences; Janssen-Cilag; Roche
Consulting or Advisory Role - Abbvie; Amgen; Janssen-Cilag; Novartis; Roche/Genentech; Takeda
Research Funding - Roche
Travel, Accommodations, Expenses - Abbvie
 
Marek Trneny
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; MorphoSys; Novartis; Roche; SOBI; Swixx BioPharma; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Autolus; Bristol-Myers Squibb; Caribou Biosciences; Genmab; Gilead Sciences; Incyte; Janssen; MorphoSys; Novartis; Roche; SOBI; Takeda
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; janssen; Roche; SOBI; Takeda
 
David Belada
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Dr. Reddy's; Genmab; Gilead Sciences; Janssen-Cilag; MorphoSys; Roche; Takeda
Research Funding - AstraZeneca (Inst); Dr. Reddy's (Inst); Genmab (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Roche; Takeda
 
Fatih Demirkan
No Relationships to Disclose
 
Panayiotis Panayiotidis
Honoraria - AbbVie; Genesis Pharma; Gilead Sciences; Janssen; Novartis
Research Funding - Abbvie; Genesis Pharma; Novartis; Roche
 
Wojciech Jurczak
Consulting or Advisory Role - Abbvie/Genentech; BeiGene; Lilly; Takeda
Research Funding - Abbvie/Genentech; AstraZeneca; BeiGene; Janssen-Cilag; Lilly; Roche; Takeda
 
Pier Zinzani
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb; Incyte; Janssen; Kite/Gilead; Kyowa Kirin International; MSD; Novartis; Recordati; Roche; SOBI; Takeda
Speakers' Bureau - AstraZeneca; BeiGene; BMS; Incyte; Janssen; Kite/Gilead; Kyowa Kirin International; MSD; Novartis; Recordati; Roche; SOBI; Takeda
 
Mary-Margaret Keating
Consulting or Advisory Role - AbbVie; Janssen; Roche
 
Sung-Soo Yoon
Honoraria - Celgene; Janssen; Novartis
Consulting or Advisory Role - Amgen; Antengene; Janssen; Novartis; Regeneron; Sanofi; Takeda
Research Funding - Chong Kun Dang Pharmaceutical Corp; JW Pharmaceutical Corporation; Kyowa Kirin; Roche/Genentech; Yuhan
 
Miklos Egyed
No Relationships to Disclose
 
Constantine Tam
Honoraria - Abbvie; Beigene; Janssen-Cilag; Loxo/Lilly; Roche/Genentech
Consulting or Advisory Role - Abbvie; BeiGene; Janssen; Loxo; Roche
Research Funding - Abbvie (Inst); BeiGene (Inst); Janssen-Cilag (Inst)
 
Nathalie Johnson
Honoraria - Abbvie; AstraZeneca; Incyte
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Gilead Sciences; Incyte; Lilly; Roche/Genentech
Research Funding - Gilead Sciences; Incyte; Roche
 
Edith Szafer-Glusman
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jennifer Lin
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
James Dean
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jutta Neuenburg
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Gottfried von Keudell
Honoraria - Abbvie; Incyte; Merck; MorphoSys; Pharmacyclics; Regeneron
Consulting or Advisory Role - Abbvie; Abbvie; Incyte; Merck; Pharmacyclics
Research Funding - Abbvie; Genmab; Regeneron
Travel, Accommodations, Expenses - Genmab